BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Julphar
Dow
QuintilesIMS
Cantor Fitzgerald
US Department of Justice
US Army
Baxter
McKinsey
Colorcon

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,579,019

« Back to Dashboard

Summary for Patent: 7,579,019
Title:Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
Abstract:The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.
Inventor(s): Tapolsky; Gilles H. (The Woodlands, TX), Osborne; David W. (The Woodlands, TX)
Assignee: Arius Two, Inc. (Raleigh, NC)
Application Number:11/069,089
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Device;

Drugs Protected by US Patent 7,579,019

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-001 Oct 23, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Subscribe
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-002 Oct 23, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Subscribe
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-003 Oct 23, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Subscribe
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-004 Oct 23, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Subscribe
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-005 Oct 23, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Subscribe
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-006 Oct 23, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Subscribe
Bdsi BELBUCA buprenorphine hydrochloride FILM;BUCCAL 207932-007 Oct 23, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE ➤ Subscribe
Bdsi BUNAVAIL buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL 205637-001 Jun 6, 2014 RX Yes No ➤ Subscribe ➤ Subscribe MAINTENANCE TREATMENT OF OPIOID DEPENDENCE ➤ Subscribe
Bdsi BUNAVAIL buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL 205637-002 Jun 6, 2014 RX Yes No ➤ Subscribe ➤ Subscribe MAINTENANCE TREATMENT OF OPIOID DEPENDENCE ➤ Subscribe
Bdsi BUNAVAIL buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL 205637-003 Jun 6, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe MAINTENANCE TREATMENT OF OPIOID DEPENDENCE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,579,019

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,800,832 Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces ➤ Subscribe
6,159,498 Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,579,019

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1079813 ➤ Subscribe
Portugal 973497 ➤ Subscribe
Japan 2010270153 ➤ Subscribe
Japan 2010265319 ➤ Subscribe
Japan 2005281322 ➤ Subscribe
Japan 2002512950 ➤ Subscribe
Japan 4619894 ➤ Subscribe
Japan 2005325140 ➤ Subscribe
Japan 3964465 ➤ Subscribe
Japan 2001508037 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Accenture
Federal Trade Commission
Chubb
Citi
Cantor Fitzgerald
Julphar
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot